Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dialysis adequacy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Dialysis adequacy. Displaying page 1 of 1.
    EudraCT Number: 2011-000455-16 Sponsor Protocol Number: CYT/Heparin_01/11 Start Date*: 2011-05-05
    Sponsor Name:CYATHUS EXQUIRERE PharmaforschungsGmbH
    Full Title: Efficacy and local tolerability of topically applied heparin (Heparin 2,400 IU/ml Cutaneous Spray) on the suitability of newly constructed primary arteriovenous Fistulas in haemodialysed patients
    Medical condition: This placebo-controlled, randomized and double-blinded pilot study aims to confirm the previous study performed by Stuard et al. (2010) by proving clinically efficacy and local tolerability of topi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003899-13 Sponsor Protocol Number: NL65803.078.18 Start Date*: 2018-12-20
    Sponsor Name:
    Full Title: The effect of IntraDialytic Parenteral Nutrition on nutritional status and quality of life in hemodialysis patients
    Medical condition: Malnutrition / Sarcopenia (loss of muscle mass) in hemodialyse patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004790-32 Sponsor Protocol Number: 204836 Start Date*: 2016-03-07
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemo...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002682-19 Sponsor Protocol Number: PHI113633 Start Date*: 2013-12-20
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and...
    Medical condition: Anemia associated with chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) GB (Completed) DK (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004851-36 Sponsor Protocol Number: 404-201-00012 Start Date*: 2020-08-25
    Sponsor Name:Otsuka Pharmaceutical (OPDC)
    Full Title: Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia ...
    Medical condition: Anemia of Chronic kidney disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    21.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    21.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004049-34 Sponsor Protocol Number: PHI116582 Start Date*: 2013-01-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombina...
    Medical condition: Anaemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005537-35 Sponsor Protocol Number: E5564-G000-301 Start Date*: 2006-08-30
    Sponsor Name:Eisai Limited
    Full Title: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis
    Medical condition: Severe Sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040047 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) AT (Completed) CZ (Completed) ES (Completed) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002206-20 Sponsor Protocol Number: MK-3475-052 Start Date*: 2014-12-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer
    Medical condition: advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DK (Completed) IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 16:16:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA